China’s Dragon Awakens: How It Aims to Lead the Global Fight Against Alzheimer’s

China is rapidly advancing its national Alzheimer’s disease research agenda, positioning itself as a potential global leader in the fight against neurodegenerative disorders through massive state investment, large-scale clinical trials, and integration of artificial intelligence into biomarker discovery and drug development pipelines.

Key Clinical Takeaways:

• China’s Alzheimer’s research initiative is backed by over $1.5 billion in state funding since 2021, targeting early detection and novel therapeutics.
• Recent Phase III trials of domestically developed amyloid-targeting monoclonal antibodies demonstrate signal of cognitive slowing, though safety profiles require further scrutiny.
• Integration of AI-driven neuroimaging and multi-omic data from China’s Kailuan and China Health and Retirement Longitudinal Study (CHARLS) cohorts is accelerating biomarker validation.

The scale of China’s commitment to Alzheimer’s research marks a significant shift in the global neuroscience landscape. With over 15 million people aged 60 and above currently living with dementia in China—a number projected to exceed 30 million by 2050—the public health imperative is immense. This urgency has driven the Chinese Ministry of Science and Technology to launch the “Brain Science and Brain-Inspired Intelligence” initiative, a 15-year plan allocating unprecedented resources to decipher the pathogenesis of Alzheimer’s disease, particularly focusing on early asymptomatic stages where intervention may be most effective. Unlike the fragmented, often industry-led trials common in Western settings, China’s approach emphasizes centralized coordination between academic hospitals, the Chinese Academy of Sciences, and biotech firms under direct state oversight.

A cornerstone of this strategy is the nationwide rollout of amyloid PET screening in urban memory clinics, supported by domestic radiotracer production. According to the longitudinal study published in Nature Medicine in 2024, which analyzed baseline data from over 8,000 participants in the CHARLS cohort, individuals with elevated cortical amyloid burden demonstrated a 4.2-fold increased risk of progressing to mild cognitive impairment within three years, even after adjusting for vascular risk factors and APOE ε4 status. This finding has validated the push for population-based screening in high-risk cohorts aged 50 and above, particularly in urban centers like Beijing and Shanghai where memory clinics now offer subsidized amyloid PET scans through municipal health programs.

On the therapeutic front, China’s State Food and Drug Administration (SFDA) granted conditional approval in late 2023 to GV-971 (sodium oligomannate), a marine-derived oligosaccharide developed by Shanghai-based Green Valley Pharmaceuticals, for the treatment of mild to moderate Alzheimer’s disease. The approval was based on the Phase III GV-971-301 trial, a multicenter, double-blind, placebo-controlled study involving 818 patients across 34 hospitals in China, which showed a statistically significant slowing of cognitive decline on the ADAS-Cog13 scale at 36 weeks (p=0.008). Notably, post-hoc analyses suggested the drug’s mechanism may involve modulation of gut microbiota-mediated neuroinflammation, reducing intestinal production of pro-inflammatory metabolites like phenylalanine and isoleucine that can cross the blood-brain barrier and activate microglia. Although, the EMA and FDA have not yet accepted GV-971 for review, citing concerns over trial duration, regional generalizability, and the need for replication in more diverse populations.

More recently, Sino Biopharmaceutical has advanced SB-001, a humanized monoclonal antibody targeting aggregated tau protein, into Phase IIb trials. Preliminary data presented at the 2025 Alzheimer’s Association International Conference (AAIC) indicated a 28% reduction in plasma p-tau217 levels over 18 months in early Alzheimer’s patients, accompanied by a trend toward slowed hippocampal atrophy on MRI. Funded by a combination of provincial innovation grants and private equity from Fosun Pharma, the SB-001 program exemplifies China’s push to develop homegrown biologics capable of competing with Western anti-amyloid and anti-tau therapies like lecanemab and donanemab. As noted by Dr. Weijie Zhang, lead neurologist at Huashan Hospital Fudan University and principal investigator of the SB-001 trial, “We are not merely replicating Western pipelines. we are targeting pathophysiological nodes—like tau propagation and neuroimmune crosstalk—that may be under-addressed in current global trials.”

Artificial intelligence is increasingly embedded in China’s Alzheimer’s research infrastructure. The Beijing Institute of Brain Disorders, in collaboration with Tsinghua University, has developed an AI platform that analyzes retinal scans and EEG patterns to predict amyloid positivity with 89% accuracy in validation cohorts, potentially offering a low-cost, scalable screening tool. This system was trained on multimodal data from over 12,000 participants in the Kailuan Study, a community-based prospective cohort in Tangshan with deep phenotyping of cardiovascular and neurological outcomes. Such innovations could prove vital in rural and tier-3 cities where access to PET scanners and cerebrospinal fluid testing remains limited.

For patients navigating early cognitive changes or family caregivers seeking diagnostic clarity, timely access to specialized memory disorder services is critical. Individuals experiencing persistent short-term memory lapses, disorientation in familiar environments, or difficulty managing finances should consider evaluation by specialists trained in neurodegenerative disease assessment. This proves strongly advised to consult with vetted board-certified neurologists with expertise in cognitive disorders, particularly those affiliated with academic medical centers participating in research networks like CHARLS or ADNI-China. Similarly, families managing complex behavioral symptoms in later-stage Alzheimer’s may benefit from coordinated care models offered by specialized memory care units that integrate pharmacological management with non-pharmacological interventions such as cognitive stimulation therapy and occupational therapy.

On the B2B front, global pharmaceutical companies seeking to partner with Chinese research institutions or access real-world data from China’s expansive clinical networks must navigate a evolving regulatory landscape. Recent updates to the SFDA’s guidelines on international clinical trials emphasize data localization requirements and mandatory collaboration with Chinese principal investigators. To ensure compliance and avoid delays in trial initiation or data transfer, sponsors are increasingly engaging healthcare compliance attorneys with specific expertise in cross-border neuroscience research and SFDA submissions.

China’s ascent in Alzheimer’s research is not about displacing existing Western-led efforts but expanding the global capacity to understand a disease that defies simple mechanistic explanation. By combining scale, state coordination, and innovation in biomarkers and therapeutics, China is contributing essential data on disease progression in underrepresented populations and exploring novel therapeutic angles—particularly in the gut-brain axis and neuroimmunomodulation—that may benefit patients worldwide. The true measure of success will lie not in national primacy but in whether these efforts translate into safer, more effective, and accessible interventions for the millions living with Alzheimer’s disease, wherever they reside.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*